Biotech developing small-molecule radioligand therapies targeting fibroblast activation protein for cancer.
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Series A Actithera closed a $75.5M Series A co-led by M Ventures, Hadean Ventures, Sofinnova Partners and 4BIO Capital to advance its radioligand therapy pipeline into the clinic. | $75.5M |